Autoimmune lymphoproliferative syndrome: Etiology, diagnosis, and management

Pediatric Drugs

Volumn 5, Issue 3, 2003, Pages 185-193

  Van Der Werff Ten Bosch, Jutte ^a,b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 8; CD45 ANTIGEN; CORTICOSTEROID; FANSIDAR; FAS ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPER FAMILY MEMBER 6; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CHEMOTHERAPY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; GENE MUTATION; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPERSPLENISM; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISEASE; MULTIGENE FAMILY; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SPLENECTOMY; TREATMENT OUTCOME;

EID: 0037232382     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305030-00005     Document Type: Review

References (70)

1. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5
2. Kerr J, Wyllie A, Currie A. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57
3. Jenkins M, Keir M, McCune JM. Fas is expressed early in human thymocyte development but does not transmit an apoptotic signal. J Immunol 1999; 163: 1195-204
4. Lowin B, Hahne M, Mamnann C, et al. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-2
5. Mogil RJ, Radvanyi L, Gonzalez-Quintial R, et al. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 1995; 7: 1451-8
6. Dhein J, Walzac H, Baumler C, et al. Autocrine T-cell suicide mediated by APO-1(Fas/CD95). Nature 1995; 373: 438-41
7. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the TNF/NGF receptor superfamily. J Biol Chem 1992; 15: 10709-15
8. Ju S, Panka D, Cui H, et al. Fas (CD95)/FasL interaction required for programmed cell death after T cell activation. Nature 1995; 373: 444-8
9. Garonne P, Neidhardt E, Garcia E, et al. Fas ligation induces apoptosis in CD40-activated human B lymphocytes. J Exp Med 1995; 182: 1265-73
10. Dhein J, Daniel P, Trauth B, et al. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992; 149: 3166-73
11. Kischkel F, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (FAS/CD95) associated proteins form a death-inducing signal complex (DISC) with the receptor. EMBO J 1995; 4: 5579-88
12. Itoh N, Nagata S. A novel protein domain required for apoptosis-mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932-7
13. Wang J, Chun HJ, Wong W, et al. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 2001; 98: 13884-8
14. Salvesen G, Dixit V. Caspases, intracellular signaling by proteolysis. Cell 1997; 91: 443-6
15. Zheng T, Schlosser S, Dao T, et al. Caspase-3 controls both cytoplasmatic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc Natl Acad Sci USA 1998; 95: 13618-23
16. Andrews B, Eisenberg R, Theofilopoulos A, et al. Spontanous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978; 166: 1198-203
17. Watanabe-Fukunaga R, Brannan C, Copeland N. et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-7
18. Takahashi T, Tanaka M, Brannan C, et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76
19. Sneller C, Straus S, Jaffe E. et al. A novel lymphoproliferative/autoimmune syndrome resembling routine 1pr/g1d disease. J Clin Invest 1992; 90: 334-41
20. Fisher G, Rosenberg F, Straus S, et al. Dominant interfering fas gene mutations impair apoptosis in a human autolmmune lymphoproliferative syndrome. Cell 1995; 81: 935-46
21. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliterative syndrome and autoimmunity. Science 1995; 268: 1347-9
22. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatrics 1967; 70: 891-9
23. Weisdorf SA, Krivit W. Paucity of splenic germinal centers: a new and unique splenomegaly syndrome including dysfunctional immune system. Clin Immunol Immunopathol 1982; 23: 492-500
24. Horowitz SD, Borcherding W, Hong R. Autoimmune hemolytic anemia as a manifestation of T-suppressor-cell deficiency. Clin Immunol Immunopathol 1984; 33: 313-23
25. McKinley RA, Kwan YL, Lam-Po-Tang PR. Familial splenomegaly syndrome with reduced circulating T helper cells and splenic germinal centre hypoplasia. Br J Haematol 1987; 67: 393-6
26. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutation in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoiminanity. N Engl J Med 1996; 335: 1643-9
27. Straus SE, Sneller M, Lenardo MJ, et al. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999; 130: 591-601
28. Dianzani U, Bragardo M, DiFranco D, et al. Deficiency of Fas apoptosis pathway without fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 1997; 89: 2871-9
29. Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98: 47-58
30. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419: 395-9
31. Wu J, Wilson J, He J, et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98: 1107-13
32. Jackson P, Puck J. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr 1999; II: 521-7
33. Pensati L, Costanzo A, Ianni A, et al. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997; 113: 1384-9
34. Sheller M, Wang Y, Dale J, et al. Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89: 1341-8
35. Bettinardi A, Brugnoni D, Quiros-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 1997; 89: 902-9
36. Kasahara Y, Wada T, Niida Y, et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol 1998; 10: 195-202
37. van der Werff ten Bosch J, Demanet C, Balduck N, et al. The use of the anti malaria drug Fansidar (pyrimethamine and sulfadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. Br J Haematol 1998; 102: 578-81
38. Sleight B, Prasad V, DeLaat C. et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 1998; 22: 375-80
39. Peters A, Kohfink B, Martin H, et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol 1999; 27: 868-74
40. Rieux-Laucat F, Blachère S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant interfering expression of the clinical phenotype. Blood 1999; 94: 2575-82
41. Aspinall AI, Pinto A, Auer IA, et al. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia. Blood Cells Mol Dis 1999; 25: 227-38
42. Sbenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr 2000; 136: 682-7
43. Bader-Meunier B, Rieux-Laucat F, Croisille L. et al. Dyserythropoiesis associated with a Fas-deficient condition in childhood. Br J Haematol 2000; 108: 300-4
44. Fang BS, Sheller MC, Straus SE, et al. Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome. Am J Hematol 2000; 64: 214-7
45. van der Burg M, de Groot R, Comans-Bitter W, et al. Autoimmune lymphoproliferative syndrome (ALPS) in a child from cosanguineous parents: a dominant or recessive disease. Pediatr Res 2000; 47: 336-43
46. Hanlon MG, Gacis ML, Kakakios AM, et al. Investigation of suspected deficient Fas-mediated apoptosis in a father and son. Cytometry 2001; 43: 195-8
47. van den Berg A, Maggio E, Diepstra A. et al. Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma. Blood 2002; 99: 1492-4
48. van der Werff ten Bosch J, Schotte P, Ferster A. et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol 2002; 117: 176-88
49. Strobel P, Nanan R, Gattenlohner S. et al. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency. Am J Surg Pathol 1999; 23: 829-37
50. Ramenghi U, Bonissoni S, Migliaretti G, et al. Deficiency of the fas apoptosis pathway without fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 2000; 95: 3176-82
51. van der Werff ten Bosch J, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III: an indefinite disorder. Leak Lymphoma 2001; 41: 55-65
52. Boehler T, Posovszky C, Fulda S, et al. Defective CD95-induced apoptosis in children with autoimmune lymphoproliferative syndrome (ALPS)/Canale-Smith syndrome (CSS) in the absence of CD95 mutations [abstract]. Blood 1999; 94 (Suppl. 1 Pt 2): 50B
53. Posovszky C, Scheuerpflug C, Fuchs H, et al. CD95-death-inducing signaling complex formation in autoimmune lymphoproliferative syndrome/Canale-Smith syndrome (ALPS/CSS). Eur J Pediatr 2001; 160: R17-28
54. Le Deist F, Emile J, Rieux-Laucat F, et al. Clinical, immunological and pathological consequenses of Fas-deficient condition. Lancet 1996; 348: 719-23
55. van der Werff ten Bosch J, Delabie J. Böhier T. et al. Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferalive syndrome type II. Br J Haematol 1999; 106: 1045-8
56. Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome: a human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000; 47: 1291-310
57. Carter LB, Procter JL, Dale JK, et al. Description of serologic features in autoimmune lymphoproliferative syndrome. Transfusion 2000; 40: 943-8
58. Fuss I, Strober W, Dale J, et al. Characteristic T helper 2 cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity. J Immunol 1997; 158: 1912-8
59. Lira M, Straus S, Dale J. et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol 1998; 153: 1541-50
60. Infante A, Britton H, DeNapoli T, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs apoptosis. J Pediatr 1998; 133: 629-33
61. Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 2001; 98: 2466-73
62. Boulanger E, Rieux-Laucat F, Picard C, et al. Diffuse large B-cell non-Hodgkin's lymphoma in a patient with autoimmune lymphoproliferative syndrome. Br J Haematol 2001; 113: 432-4
63. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98: 194-200
64. National Human Genome Research Institute. Autoimmune lymphoproliferative syndrome database [online]. Available from URL: http://www.nhgri.nih.gov/DIR/GMBB/ALPS [Accessed 2003 Jan 29]
65. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas:genotype influence penetrance. Am J Hum Genet 1999; 64: 1002-14
66. Benkerrou M, Le Deist F, Villartay J, et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 1997; 27: 2043-7
67. Scaffidi C, Kirchhoff S, Krammer PH, et al. Apoptosis signaling in lymphocytes. Curr Opin Immunol 1999; 11: 277-85
68. Lopatin U, Yao X, Williams RK, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood 2001; 97: 3161-70
69. Avila N, Dwyer A, Dale J, et al. Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis: CT and US features. Radiology 1999; 212: 257-63
70. Bleesing JJ, Brown MR, Dale JK, et al. TcR-alpha/beta(+) CD4(-) CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 2001; 100: 314-24